Alkermes

Alkermes applies neuroscience expertise to address unmet needs in psychiatric and neurological disorders, aiming to improve lives in addiction, serious mental illness, and sleep disorders.

Information about addiction or substance use disorders including alcohol dependence or alcohol use disorder (AUD) and opioid dependence or opioid use disorder (OUD).

Information about serious mental illness including bipolar I disorder and schizophrenia.

Alkermes Investigator Sponsored Studies (ISS) program supports investigator research designed and conducted by independent clinicians and scientists.

Video features Alkermes leaders speaking about key symptoms of narcolepsy, a chronic neurological disorder.

Ishani Landry, Alkermes’ Vice President of Clinical Pharmacology and DMPK, discusses her passion for neuroscience and its role in the company’s investigational orexin biology program.

Jeff Harris shares his perspective on leadership and advocacy in recognition of Mental Health Awareness Month.

Alkermes' Chief Medical Officer, Dr. Craig Hopkinson, recently published an article in Pharma Tech Outlook.

Gavin Pattison shares his perspective on environmental responsibility and sustainability at Alkermes.

Janine Shea, Alkermes’ 2026 HBA Luminary honoree, reflects on her career journey, leadership philosophy and shares advice for women building careers in life sciences.

Sharing stories of patients, employees and communities. View the latest Alkermes press releases, stories and news.

Alkermes offers pharmaceutical and biotechnology careers in the United States and Dublin, Ireland.

Steve Schiavo, Alkermes’ Head of HR, celebrates the 2025 class of interns.

Alkermes promotes diversity, inclusion, and belonging across its business operations.

Alkermes honors Susan Colby as the 2024 Healthcare Businesswomen’s Association Rising Star.

Alkermes discloses drug prices, including LYBALVI (olanzapine/samidorphan), to Vermont prescribers.

Alkermes develops medicines for psychiatric and neurological disorders, including addiction, serious mental illness, and sleep disorders like narcolepsy and idiopathic hypersomnia.

External recognition is a testament to Alkermes' commitment to being an employer of choice and a responsible corporate citizen.

Alkermes integrates corporate responsibility into its work, focusing on positive impacts for employees, communities, and society.

Alkermes' Waltham, Massachusetts location includes corporate offices and R&D and is located in the greater Boston area.

Alkermes provides contact information for research, business development, technology, contract pharma services, and investor/media relations.

Alkermes’ Wilmington, Ohio facility is a manufacturing site employing over 500 people.

Alkermes plc develops medicines in neuroscience.

Alkermes' General Certificate of Conformity certifying that their products comply with all applicable rules, bans, standards, or regulations enforced by the Consumer Product Safety Commission.

Alkermes manages its social media channels responsibly to engage effectively.

These Terms of Use describe the terms and conditions applicable to use by healthcare professionals of the Alkermes website.